BCAL Diagnostics (ASX:BDX) is dedicated to the early diagnosis of breast cancer, aiming to facilitate early intervention and enhance outcomes for women. Over the past decade, BCAL has engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. BCAL is currently focused on improved screening for breast cancer in women via its innovative blood test BREASTEST ®. BCAL Diagnostics Co-Founder and Executive Chair Jayne Shaw joins The Stock Network’s Lel Smits to discuss:
🧪 Advancing efforts to improve breast cancer diagnostics
🩺 Launching BREASTEST ® into the market
👉 Making it available for all women alongside mammogram
Watch the full interview ⚡ https://youtu.be/g31w209K29E